Arrythmia promotes Salvatore Emma, Jr. to CEO
Arrythmia Research Technology (NYSE:HRT) said on April 9 that Salvatore Emma, Jr. has been named president and CEO of the Fitchburg, Mass.-based medical device company. He was also appointed to the company’s board of directors.
Emma started at Arrhythmia in 2007 and previously worked as an information systems consultant for Munters Corporation, Lawrence Pumps and Convergent Energy.
Alphatec Spine CEO steps into the corner office at IlluminOSS Medical
IlluminOSS Medical named Dirk Kuyper CEO. The privately-held East Providence, R.I.-based orthopedic device company lured Kuyper over from his position as president and CEO of Alphatec (NSDQ:ATEC).
Kuyper spent 17 years of his career at Aesculap, a subsidiary of B. Braun Medical. He has experience in sales and marketing at various medical device companies and served as a captain in the U.S. Army.
Kinetic Concepts names Robert Hureau VP and CFO
Robert Hureau will take on both roles of CFO and VP at Kinetic Concepts in early May. Hureau spent 6 years at Sensata Technology Holdings, where he worked as controller, CFO, chief accounting officer, and senior VP. He also previously worked at Ocean Spray Cranberries and Coca Cola.
TranS1 Inc. VP of commercial operations resigns
TranS1 (NSDQ:TSON) said it VP of commercial operations Dwayne Montgomery resigned, "in order to pursue other business opportunities," according to a company filing.
Montgomery will stay on with the company until May 1. The board of directors approved a severance package of $170,186 will be paid out in equal installments.
Insmed makes space for newly created position of chief commercial officer
Insmed named Matthew Pauls chief commercial officer, a newly created role. The Monmouth Junction, N.J.-based company created this position to oversee global commercial activities for its Arikace device for cystic fibrosis and lung infection patients.
Paul has 20 years of experience in the pharmaceutical industry, including upper management roles at Shire Pharmaceuticals, Bristol-Myers Squibb and Johnson & Johnson (NYSE:JNJ).